First New York Securities’s Teva Pharmaceuticals TEVA Stock Holding History

First New York Securities’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,000	Closed	-$56.5K	–	247
2015 Q3	$56.5K	Buy	+1,000	New	+$64.8K	0.03%	164
2014 Q4	–	Sell	-50	Closed	-$2.79K	–	512
2014 Q3	$24.3K	Buy	+50	New	+$2.65K	0.02%	322

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First New York Securities's TEVA Position: Q4 2015 in Review

First New York Securities sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 1,000 shares — an estimated $56.5K sold.

First New York Securities first reported a position in TEVA in Q3 2014 and held it in 2 quarters. The position peaked at $56.5K in Q3 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

First New York Securities reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
First New York Securities sold 1,000 Teva Pharmaceuticals shares in Q4 2015, an estimated $56.5K.
First New York Securities first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 2 quarters.
First New York Securities's Teva Pharmaceuticals position peaked at $56.5K in Q3 2015.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on First New York Securities's 13F filing for Q4 2015, filed 25 Jan 2016.